A Phase 1 interventional study of Anti-HIV Immune Serum Globulin (Human) in HIV Infections, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-02-20.
Sponsored by Abbott · Phase 1, Interventional, and Treatment
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.
This study's enrollment of 12 is below the median of 83 across 3,251 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →Abbott is the lead sponsor of 350 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Required with a diagnosis of AIDS:
Active substance abuse.
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abbott